Compare Rivian Automotive, Inc. (RIVN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs ResMed Inc. — how do they compare? Rivian Automotive, Inc. trades at $17.41 (market cap $25.71B), while ResMed Inc. trades at $194.69 (market cap $28.40B). The key difference: Rivian Automotive, Inc. and ResMed Inc. are close in size by market cap, and ResMed Inc. pays a 1.23% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals.
| RIVN | RMD | |
|---|---|---|
Market Cap | $25.71B | $28.40B |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $293.73 |
52-Week Low | $11.64 | $182.82 |
Enterprise Value | $27.45B | $27.58B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $17.76, up 1.75% on the day, with a neutral technical outlook and bullish moving averages. The company continues to post significant losses, with a net income margin of -63.62% in 2025, though revenue grew to $5.39 billion. Recent news highlights focus on the upcoming R2 vehicle launch and a challenging EV market environment.
Rivian's investment case hinges on successful execution of the R2 launch and path to profitability, but faces substantial risks from cash burn, competition, and macroeconomic pressures. Analyst consensus is a Buy with a $19.22 price target, suggesting moderate upside potential from current levels if operational improvements materialize.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
